BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $11.80 Average PT from Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.80.

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a report on Thursday, June 27th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of BioXcel Therapeutics in a report on Friday, May 10th.

Insider Buying and Selling

In related news, CEO Vimal Mehta sold 126,014 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $1.63, for a total transaction of $205,402.82. Following the completion of the transaction, the chief executive officer now owns 7,811,515 shares in the company, valued at approximately $12,732,769.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 128,520 shares of company stock worth $208,611 in the last 90 days. 35.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of BioXcel Therapeutics during the 4th quarter worth approximately $176,000. Apollon Wealth Management LLC acquired a new position in BioXcel Therapeutics during the 4th quarter valued at approximately $31,000. Truist Financial Corp acquired a new position in BioXcel Therapeutics during the 4th quarter valued at approximately $32,000. Pennant Investors LP acquired a new position in BioXcel Therapeutics during the 4th quarter valued at approximately $248,000. Finally, Tower Research Capital LLC TRC increased its stake in BioXcel Therapeutics by 239.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,832 shares of the company’s stock valued at $41,000 after purchasing an additional 9,754 shares in the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Price Performance

BioXcel Therapeutics stock opened at $0.99 on Friday. The stock has a market cap of $37.15 million, a price-to-earnings ratio of -0.19 and a beta of 0.32. BioXcel Therapeutics has a 1 year low of $0.97 and a 1 year high of $7.99. The firm has a 50-day moving average of $1.30 and a two-hundred day moving average of $2.27.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.19). The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.42 million. During the same period last year, the business posted ($1.84) earnings per share. Research analysts expect that BioXcel Therapeutics will post -2.74 earnings per share for the current year.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.